Table 6.

Adverse events (safety population) ^a

	Number (%) of patients [a]
	SZC (N = 91)	Placebo (N = 90)
Any adverse event	43 (47.3)	47 (52.2)
Acute cardiac failure	2 (2.2)	1 (1.1)
Chronic cardiac failure	9 (9.9)	4 (4.4)
Chronic kidney disease	6 (6.6)	4 (4.4)
Viral upper respiratory tract infection	6 (6.6)	3 (3.3)
Hypotension	4 (4.4)	1 (1.1)
Nasopharyngitis	4 (4.4)	3 (3.3)
Constipation	3 (3.3)	2 (2.2)
Any serious adverse event (including events resulting in death)	14 (15.4)	10 (11.1)
Death	1 (1.1)	1 (1.1)
Infection	2 (2.2)	2 (2.2)
Cardiac disorders	8 (8.8)	5 (5.6)
Acute myocardial infarction	2 (2.2)	1 (1.1)
Unstable angina	0 (0.0)	1 (1.1)
Atrial fibrillation	1 (1.1)	0 (0.0)
Acute cardiac failure	2 (2.2)	1 (1.1)
Chronic cardiac failure	2 (2.2)	2 (2.2)
Myocardial fibrosis	1 (1.1)	0 (0.0)

^a Number of patients with adverse events that occurred during the study, on and off treatment, among patients who received at least one dose of the study medication.

Abbreviation: SZC, sodium zirconium cyclosilicate.